AI assistant
Sending…
Tempest Therapeutics, Inc. — Director's Dealing 2015
Apr 9, 2015
34632_dirs_2015-04-09_416b1bf4-117d-4335-944b-84f0f60ab608.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2015-04-09
Reporting Person: TZIANABOS ARTHUR (President and CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-04-09 | Common Stock | P | 225 | $28.77 | Acquired | 400 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1000 | Indirect |
More from Tempest Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
Jun 8
Board/Management Information
2026
Jun 4
Regulatory Filings
2026
Jun 1
Board/Management Information
2026
May 29
Delisting Announcement
2026
May 22
Board/Management Information
2026
May 22
Interim / Quarterly Report
2026
May 14
Earnings Release
2026
May 14
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Apr 10